Leerink Swann Reiterates “Outperform” Rating for Tesaro Inc. (TSRO)
Tesaro Inc. (NASDAQ:TSRO)‘s stock had its “outperform” rating reissued by equities researchers at Leerink Swann in a research report issued on Monday. They presently have a $115.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $108.00. Leerink Swann’s target price would indicate a potential downside of 0.29% from the stock’s previous close.
TSRO has been the subject of several other reports. RBC Capital Markets reaffirmed an “outperform” rating and issued a $122.00 price objective on shares of Tesaro in a report on Wednesday, August 24th. Wedbush reaffirmed a “buy” rating on shares of Tesaro in a report on Friday, August 5th. Robert W. Baird began coverage on shares of Tesaro in a report on Monday, July 18th. They issued an “outperform” rating and a $105.00 price objective for the company. Citigroup Inc. raised their price objective on shares of Tesaro from $90.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, August 8th. Finally, Royal Bank Of Canada raised their price objective on shares of Tesaro from $122.00 to $128.00 and gave the stock an “outperform” rating in a report on Monday. One analyst has rated the stock with a sell rating, one has issued a hold rating and thirteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $109.76.
Shares of Tesaro (NASDAQ:TSRO) opened at 115.33 on Monday. Tesaro has a 12 month low of $29.51 and a 12 month high of $122.89. The firm’s market capitalization is $5.92 billion. The firm’s 50-day moving average is $97.53 and its 200 day moving average is $70.11.
Tesaro (NASDAQ:TSRO) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.28) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.71) by $0.43. The company earned $36.60 million during the quarter, compared to the consensus estimate of $4.98 million. Tesaro had a negative net margin of 783.97% and a negative return on equity of 205.63%. During the same period last year, the firm earned ($1.51) EPS. On average, equities research analysts anticipate that Tesaro will post ($7.36) EPS for the current year.
In other news, SVP Martin H. Jr. Huber sold 408 shares of the firm’s stock in a transaction on Thursday, September 22nd. The shares were sold at an average price of $108.12, for a total transaction of $44,112.96. Following the sale, the senior vice president now owns 1,250 shares in the company, valued at approximately $135,150. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Jeffrey H. Hanke sold 29,166 shares of the firm’s stock in a transaction on Tuesday, August 30th. The shares were sold at an average price of $86.04, for a total transaction of $2,509,442.64. Following the sale, the vice president now owns 29,166 shares in the company, valued at approximately $2,509,442.64. The disclosure for this sale can be found here. Insiders own 40.50% of the company’s stock.
Several hedge funds have recently bought and sold shares of TSRO. KCG Holdings Inc. bought a new stake in Tesaro during the second quarter valued at $228,000. Quantitative Systematic Strategies LLC bought a new stake in Tesaro during the second quarter valued at $240,000. Bluestein R H & Co. bought a new stake in Tesaro during the second quarter valued at $252,000. Neuberger Berman Group LLC bought a new stake in Tesaro during the second quarter valued at $256,000. Finally, Amalgamated Bank bought a new stake in Tesaro during the second quarter valued at $260,000. Hedge funds and other institutional investors own 88.81% of the company’s stock.
Tesaro Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related companies with MarketBeat.com's FREE daily email newsletter.